TSO 500 ctDNA v2
Simple blood sample. Deep insights. One comprehensive panel
A comprehensive, noninvasive liquid biopsy (ctDNA) lab developed test for solid tumors - enabling biomarker discovery, clinical trial enrollment, and longitudinal monitoring - empowering data-driven decisions even when tumor tissue is limited or unavailable.
- 514 cancer-relevant genes
- SNVs and InDels – 514 genes
- CNVs – 58 genes
- Fusions – 23 genes
- IO gene signatures (bMSI; bTMB score)
- High performance ctDNA assay
| Variant Class | Analytical Sensitivity | Specificity | Accuracy | LOD* |
|---|---|---|---|---|
| SNVs/InDels | 92.01% | 99.80% | 99.65% | 0.23% |
| CNVs | 95% | 99.86% | 99.82% | 1.20 fold |
| Fusions | 100% | 100% | 100% | 0.5% |
*LOD90 at 30ng input
CTA style
Default